Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Closed Solicitation Posted
- Solicitation number
- HT9402-25-Q-9102
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Antonio, Texas 78230, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Defense (DoD) Defense Health Agency is soliciting quotes from pharmaceutical manufacturers for its Uniform Formulary (UF) Blanket Purchase Agreement and Additional Discount Program. The procurement targets newly approved drugs in three specific therapeutic categories: Itovebi (Oncological Agents - Breast Cancer), Miplyffa (Neurological Agents), and Opipza (Antipsychotic Agents). The DoD Pharmacy and Therapeutics (P&T) Committee will evaluate these pharmaceutical agents based on their relative clinical and cost effectiveness, with the goal of determining their placement on the military's pharmacy formulary. Manufacturers must submit detailed pricing information, including Federal Ceiling Prices, non-FAMP prices, and Wholesale Acquisition Cost pricing for various scenarios. Key dates include a pre-quotation teleconference on December 4, 2024, and a final quote submission deadline of December 19, 2024, with the P&T Committee review scheduled for February 2025.
The solicitation is not set aside for any specific business category and will be open to all qualified pharmaceutical manufacturers. While specific award values are not explicitly stated, the opportunity covers pharmaceutical agents for the Military Health System's pharmacy benefits program. The place of performance is located in San Antonio, Texas, with quotes potentially impacting drug pricing and availability across military treatment facilities, mail order pharmacies, and TRICARE retail networks. Manufacturers can submit pricing for up to 10 National Drug Code (NDC) variations per drug, with provisions for potential price adjustments after one year based on the Producer Price Index. The agreement terms require manufacturers to hold quoted prices for 180 days, and the final formulary placement will determine cost-sharing classifications such as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary status.
Notice text
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following February 2025 newly approved drugs will be reviewed:
a. Itovebi - Oncological Agents - Breast Cancer
b. Miplyffa - Neurological Agents Miscellaneous - NA
c. Opipza - Antipsychotic Agents - Atypical
The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9102.
Pre-quotation teleconference is on December 4, 2024. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1. no later than the date stated in Part 2.3.2.
Files
| File | Type | Posted |
|---|---|---|
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| RFQ HT9402-25-Q-9102 NAD.pdf | ||
| Price List - Miplyffa - Neurological Agents Miscellaneous - NA.xlsx | XLSX spreadsheet | |
| Price List - Opipza - Antipsychotic Agents - Atypical.xlsx | XLSX spreadsheet | |
| Price List - Itovebi - Oncological Agents - Breast Cancer.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity